|
Based on the information provided, no conclusions can be made.As reported, patient experienced postoperative left breast infection.Medical affairs has assessed the patient¿s postoperative course as being serious and likely related to the study device.Review of the device history records confirmed the device was manufactured to specification.Infection is a known inherent risk of the surgery/use and listed as a possible complication in the adverse reaction section of the instruction for use (ifu) supplied with the device.In regards to infection the warnings section of the ifu states, "if an infection develops, treat the infection aggressively.An unresolved infection may require removal of the scaffold." this mdr reports the ae of infection.An additional mdr was submitted to report additional ae of incision site complication.This mdr report is related to a retrospective study conducted to proactively gather real-world evidence on the use and safety of the p4hb product family, including galaflex scaffold, galaflex 3d, and galaflex 3dr.All safety events from the study are adjudicated by the bd medical monitor for an independent assessment of severity and relatedness.In an abundance of caution, events for which relatedness cannot be ruled out are processed for mdr reporting.Not returned - remains implanted.
|
|
Per clinical trial (b)(6): on (b)(6) 2018, patient underwent bilateral revision reduction; superior pedicle using a full vertical and horizontal t incision.Two pieces of galashape (galaflex 3d) were used.No concomitant procedures were done.On (b)(6) 2018, right breast infection was reported.Additional details include right breast swelling and fever with drain placement.Treatment was medication (augmentin, cipro, bactrim, medrol) resolved without sequelae on unknown date.Review by medical affairs identifies the infection as likely related to the device and serious.
|